Charles River Laboratories CRL U.S. — Total Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's u.s. — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's U.S. — total revenue?
- Charles River Laboratories (CRL) reported U.S. — total revenue of $543.81M in Q1 2026.
- How has Charles River Laboratories's U.S. — total revenue changed year-over-year?
- Charles River Laboratories's U.S. — total revenue increased by 1.3% year-over-year, from $536.96M to $543.81M.
- What is the long-term trend for Charles River Laboratories's U.S. — total revenue?
- Over 4 years (2021 to 2025), Charles River Laboratories's U.S. — total revenue has grown at a 2.6% compound annual growth rate (CAGR), from $1.93B to $2.14B.
- What does U.S. — total revenue mean?
- This metric represents the total gross income generated by the company's operations within the United States geographic segment. It reflects the demand for research models, services, and laboratory support provided to domestic clients, including pharmaceutical and biotechnology firms. Tracking this figure helps investors assess the company's market penetration and revenue stability within its primary domestic market.